The cost of a one-time advanced medicinal therapy can be upwards of $350,000 per patient. And this does not include hospital costs.
Such a high price is not sustainable in highly developed nations, let alone in low- and middle-income countries.
This leaves many people without access to potential curative medicines, particularly those in marginalized, impoverished or underserved communities.
It is a basic human right to have access to curative medicines when suffering from a serious or terminal disease.
Together we can accelerate the development of cures and improve their access by driving down their cost.
How do we accomplish this?
First, we empower our community with knowledge of cutting-edge advanced medicinal research and how cures are made.
Second, we aim to lower the cost and improve access by helping hospitals and health systems manufacture advanced medicines at the place of care.
Third, we support specific cure projects that, if successful, would make treatment available to all in need at an affordable and sustainable cost.
Fourth, we work with our corporate partners to improve the economics of manufacturing advanced medicines at the place of care.
Currently, we’re leading our cure development program with a potential curative CAR-T cell therapy for HIV/AIDS, a disease that affects over 37 million people globally, including 1.8 million children.
Our development program also includes a curative stem cell gene therapy for Sickle Cell Disease and β-Thalassemia, diseases that affect hundreds of millions of lives. A pipeline of advanced medicines is being developed by Caring Cross and its partners with the goal of making them affordable and accessible for all who need them.
By supporting Caring Cross with your donation, you help us drive towards our goal of creating access to cures for every patient, without exception.
